Akorn Inc

Most Recent

  • uploads///Graph
    Company & Industry Overviews

    Akorn’s Macro-Level Challenges in the Generic Drug Segment

    Although generic drugs only account for 3% of the total healthcare costs in the US, regulators continue to be concerned about rising generic pricing.

    By Margaret Patrick
  • uploads///dollar _
    Company & Industry Overviews

    Why Akorn Stock Crashed Yesterday

    Akorn stock fell dramatically from $12.98 on September 28 to $5.36 on October 1 after the Delaware Court of Chancery ruled against the company and in favor of Fresenius.

    By Margaret Patrick
  • uploads///graph_
    Company & Industry Overviews

    Could Mylan See a Rise in Net Profit Margins in 2017?

    In 2Q17, Mylan (MYL) reported gross profit margins of 54.0%, which was lower than 56.0% reported in 2Q16.

    By Margaret Patrick
  • uploads///Chart  BMY
    Miscellaneous

    How Bristol-Myers Squibb Stock Has Performed in 2Q17

    A look at Bristol-Myers Squibb Headquartered in New York City, Bristol-Myers Squibb (BMY) is an American pharmaceutical company that develops innovative medicines in various therapeutic areas, including cardiovascular, neuroscience, immunoscience, oncology, and virology. Stock price performance While Bristol-Myers Squibb’s stock price has risen ~3.8% in 2Q17, it had fallen ~5.4% year-to-date as of July 7, […]

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Teva’s Research Pipeline and Generic Product Launches in 2016

    The combined Teva Pharmaceutical–Allergan Generics company filed 65 ANDAs (Abbreviated New Drug Applications) in 2015.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Akorn in 2016: What Are Its Key Risk Factors?

    In addition to industry-specific risks faced by all generic pharmaceutical players, Akorn (AKRX) faces certain company-specific risks.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Teva Pharmaceutical Expected to See Strong Revenue Growth in 2016

    In 2016, Teva Pharmaceutical (TEVA) expects to earn revenues of $22.0 billion–$22.5 billion. This includes contribution from sales of Allergan Generics products.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Teva Pharmaceutical: A Successful Bond Financing Program in 2016

    To finance the acquisition of Allergan Generics (AGN), Teva Pharmaceutical (TEVA) successfully completed a global bond offering on July 21, 2016.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Teva Aims to Improve Its Position with Actavis Generics Acquisition

    Teva Pharmaceutical expects to benefit from improved productivity after the completion of the deal with Actavis Generics.

    By Margaret Patrick
  • uploads///Graph Part  Dec
    Company & Industry Overviews

    Agios Initiates Phase 1b Trial of AG-221 or AG-120: Stock Up 14%

    Agios Pharmaceuticals (AGIO) stock rose 14% after it announced the initiation of the Phase 1b trial of either AG-221 or AG-120.

    By Peter Neil
  • uploads///Graph Part
    Company & Industry Overviews

    Key for Investors: How Are Biotech Stocks Trending?

    Dyax (DYAX) had stocks that fell out of the 100-day moving averages. Dyax reported revenue of $26.4 million and a net loss of $8.4 million.

    By Peter Neil
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.